Creabilis SA

A clinical stage European biotechnology company addressing unmet medical needs in serious dermatological and inflammatory diseases.

CT327 - TrkA Kinase Modulation
CT637 - Inflammatory & auto-immune disorders
CT340 - LSE modified kinase inhibitor
LSE technology - Creating new chemical entities ideal for topical application

Details Contacts

A novel topically
applied TrkA kinase
inhibitor.

A new biological approach to the treatment of significant inflammatory conditions.

LSE modified kinase inhibitor.

Creating new chemical
entities ideal for
topical application.

May03

Creabilis appoints Dr Simon Russell as Chief Business Officer.
Read more »

Mar26

Creabilis selected to present at BioTrinity 2012.
Read more »

Feb29

Creabilis Announces Start of Phase IIb Trial of TrkA Kinase Inhibitor CT327 in Psoriasis.
Read more »